🇺🇸 FDA
Patent

US 10874676

Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome

granted A61KA61K2300/00A61K31/137

Quick answer

US patent 10874676 (Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome) held by ESSENTIALIS, INC. expires Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ESSENTIALIS, INC.
Grant date
Tue Dec 29 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 24 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
12
CPC classes
A61K, A61K2300/00, A61K31/137, A61K31/155, A61K31/549